Oncolytic virotherapy in head and neck cancer

被引:0
作者
Runge, Annette [1 ]
Petersson, Monika [2 ]
Riechelmann, Herbert [1 ]
机构
[1] Med Univ Innsbruck, Univ Klin Hals Nasen & Ohrenheilkunde, Anichstr 35, A-6020 Innsbruck, Austria
[2] ViraTherapeut GmbH, Rum, Austria
关键词
Head and Neck Cancer; Oncolytic Virus; Tumor Microenvironment; Immune Response; Genetic Engineering; PHASE-I; ADENOVIRUS; COMBINATION; REOVIRUS; EFFICACY; DELIVERY; RECEPTOR; MUTANT; TUMORS; TRIAL;
D O I
10.1055/a-1901-9214
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective Oncolytic viruses (OV) infect and kill cancer cells and elicit an antitumoral immune response. With their potential to break through tumor immunoresistance, OV might be a future combination treatment option in patients with advanced head and neck cancer (HNC). Modes of action, biological modifications, handling and side effects of OV for treatment of HNC are reviewed. Results of preclinical and clinical trials are reported. Methods Publications and clinical trials dealing with OV and HNC were searched in PubMed and international platforms for clinical study records. Studies on preclinical and clinical trials regarding oncolytic Herpes Simplex Virus (HSV), Adenovirus, Vacciniavirus and Reovirus were selected. Results Enhanced infection and killing of tumor cells through capsid and genome modifications of OV were reported in recent preclinical studies. Most of the clinical studies were phase-I/II trials. In phase III studies, tumor regression and prolonged survival were observed after treatment with oncolytic HSV, Adenoviruses and Reoviruses. In most trials, OV were combined with chemoradiotherapy or immunotherapy. Conclusion In the published studies, OV treatment of HNC patients was safe, often well tolerated and showed promising results with regard to response and survival, especially in combination with chemoradiotherapy or checkpoint inhibitors.
引用
收藏
页码:787 / 796
页数:10
相关论文
共 47 条
  • [1] Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
    Achard, Carole
    Surendran, Abera
    Wedge, Marie-Eve
    Ungerechts, Guy
    Bell, John
    Ilkow, Carolina S.
    [J]. EBIOMEDICINE, 2018, 31 : 17 - 24
  • [2] Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy
    Bishnoi, Suman
    Tiwari, Ritudhwaj
    Gupta, Sharad
    Byrareddy, Siddappa N.
    Nayak, Debasis
    [J]. VIRUSES-BASEL, 2018, 10 (02):
  • [3] A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor Armed oncolytic adenovirus for the treatment of head and neck cancers
    Chang, Jianhua
    Zhao, Xiaoying
    Wu, Xianghua
    Guo, Ye
    Guo, Haiyi
    Cao, Junnin
    Guo, Yong
    Lou, Delun
    Yu, Dechao
    Li, Jin
    [J]. CANCER BIOLOGY & THERAPY, 2009, 8 (08) : 676 - 682
  • [4] Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
    Chesney, Jason
    Puzanov, Igor
    Collichio, Frances
    Singh, Parminder
    Milhem, Mohammed M.
    Glaspy, John
    Hamid, Omid
    Ross, Merrick
    Friedlander, Philip
    Garbe, Claus
    Logan, Theodore F.
    Hauschild, Axel
    Lebbe, Celeste
    Chen, Lisa
    Kim, Jenny J.
    Gansert, Jennifer
    Andtbacka, Robert H. I.
    Kaufman, Howard L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1658 - +
  • [5] Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers
    Choi, I-K
    Yun, C-O
    [J]. CANCER GENE THERAPY, 2013, 20 (02) : 70 - 76
  • [6] Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma
    Cooper, Timothy
    Biron, Vincent L.
    Fast, David
    Tam, Raymond
    Carey, Thomas
    Shmulevitz, Maya
    Seikaly, Hadi
    [J]. JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2015, 44
  • [7] Immunotherapy for head and neck cancer: Recent advances and future directions
    Cramer, John D.
    Burtness, Barbara
    Ferris, Robert L.
    [J]. ORAL ONCOLOGY, 2019, 99
  • [8] Armed oncolytic viruses: A kick-start for anti-tumor immunity
    de Graaf, J. F.
    de Vor, L.
    Fouchier, R. A. M.
    van den Hoogen, B. G.
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2018, 41 : 28 - 39
  • [9] A Tool for Rapid Assessment of Functional Outcomes in Patients with Head and Neck Cancer
    Dejaco, Daniel
    Riedl, David
    Gasser, Sebastian
    Schartinger, Volker Hans
    Innerhofer, Veronika
    Gottfried, Timo
    Steinbichler, Teresa Bernadette
    Riechelmann, Felix
    Moschen, Roland
    Galvan, Oliver
    Stigler, Robert
    Gassner, Robert
    Rumpold, Gerhard
    Lettenbichler-Haug, Anna
    Riechelmann, Herbert
    [J]. CANCERS, 2021, 13 (21)
  • [10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247